Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including:Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial CancerPhase III From KEYNOTE-826: Bevacizumab Subgroup Analysis Based on Protocol Specified Final Overall Survival ResultsPhase III ICON8B: Weekly DD-CT + Bev vs Q3W CT + Bev as First Line in High-Risk Epithelial Ovarian CancerHRD Testing on Cell-Free Tumor DNA From Peritoneal Fluid of Patients With Newly-Diagnosed Epithelial Ovarian CancerPresenters:Alexandra Leary, MD, PhDCo DirectorMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceDomenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyThis educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/424E3Uq

There are no comments yet.

Please log in to write the first comment.